Mr. Michael R. Minogue is the Chief Executive Officer, President and Chairman of Abiomed Inc. (NASDAQ: ABMD). Since joining in 2004, Mr. Minogue transitioned the corporate mission to heart muscle recovery through creation of breakthrough percutaneous, heart support technologies. This included the acquisition and development of new technologies such as Impella, the world’s smallest heart pump. Abiomed, a public company (ABMD) with revenues over $400 million, employs approximately 800 people with facilities in Danvers, Massachusetts, Aachen and Berlin, Germany and Tokyo, Japan.
During Mr. Minogue’s tenure, Abiomed has grown approximately 1,800% in revenue, 2,000% in market capitalization (~$4 billion) and is GAAP profitable with no debt and solid balance sheet. Abiomed has earned over 30 global regulatory approvals on new products in the United States, Europe, Japan, China and other countries.
Mr. Minogue currently represents the medical device industry by serving: on the executive board of directors for AdvaMed, and as Chairman of Medical Device Industry Consortium (MDIC), a public private partnership with the industry, government and non-profits. Mr. Minogue formerly served on the board of LifeCell Corporation (LIFC) before it was acquired in 2008. He is also a member of the Board of Managers of Bioventus LLC. Mr. Minogue is one of the co-founders and Chairman of the MedTech and BioTech Veterans Program (MVP) (www.mvpvets.org), a 501(c)(3) non-profit organization that helps military veterans network with industry mentors to discover career opportunities in the life sciences industries.
Mr. Minogue joined Abiomed from General Electric Healthcare, where he holds three patents and spent 11 years developing expertise in sales, marketing, product development and software/service operations around diagnostic imaging and treatment of cancer and cardiovascular disease. Earlier in his life, Mr. Minogue served as an Infantry officer in the U.S. Army, which included multiple distinctions including Airborne, RANGER, Desert Storm Veteran and Bronze Star. He received his Bachelor of Science degree in Engineering Management from the United States Military Academy at West Point and his MBA from the University of Chicago.
Mr. Minogue is married with five children and enjoys reading, mentoring, running, coaching, skiing and playing sports.
Dr. Seth Bilazarian joined Abiomed in 2015 and serves as our Chief Medical Officer. He is a clinical and interventional cardiologist and has performed coronary and peripheral interventions at Lahey Clinic, Boston University Medical Center, Massachusetts General Hospital and was Director of the Cardiac Catheterization Laboratory (Cath Lab) and Chief of the Cardiovascular Steering Committee at Lawrence General. He also served on the faculty as an instructor in medicine at Harvard Medical School. In 2008, he was appointed as physician advisor to the cardiac device panel of the Food & Drug Administration. Dr. Bilazarian received a Bachelor of Science in Engineering in Chemical Engineering from Tufts University an MD from University of Massachusetts Medical School. He completed his internship and residency at The Johns Hopkins Hospital in Baltimore, and cardiology and interventional cardiology fellowship at Boston University Hospital and Boston City Hospital. Dr. Bilazarian is board certified in cardiovascular medicine, nuclear cardiology, vascular ultrasound, interventional cardiology, and vascular and endovascular medicine.
Ms. Kelley Boucher joined Abiomed in September 2016. Prior to joining Abiomed, Ms. Boucher was the Head of Human Resources for Corporate Divisions at Shire Pharmaceuticals where she held multiple positions and managed the HR component of several acquisitions. Ms. Boucher has served as a Principal Consultant for Clockwork Consulting and has held Human Resources roles at Syntonix Pharmaceuticals and Digitas. Ms. Boucher brings significant experience leading organizational transformation, enabling growth through strategic talent acquisition and developing a high performance culture with a purpose. Ms. Boucher holds a Bachelor of Arts from Cornell University.
Mr. William J. Bolt joined us in June 1982 and serves as our Senior Vice President for Quality, Regulatory and Clinical Operations. He is currently responsible for the global management of clinical development, regulatory and quality functions. From 2006 to early 2015 he was responsible for global product operations which included engineering, quality and product development, and at different times, for the regulatory functions. From 2003 to 2006 he was responsible for our quality and service functions. He was responsible for all product development and engineering and the AbioCor Total Artificial heart program from 1999-2003, and for BVS and AB5000 development from 1999-2003. From 1994 to 1999, he was President of our former dental subsidiary, ABIODENT. From 1982 to 1994, he served in various roles, from Vice President of Engineering to Vice President of Operations and was responsible for the first commercial product developed by Abiomed, the BVS 5000. Mr. Bolt received both his Bachelor of Science in Electrical Engineering and Master of Business Administration from Northeastern University.
Mr. Andrew J. Greenfield is currently the Vice President and General Manager of Healthcare Solutions & Global Marketing. Since joining Abiomed in 2005 as the Vice President of Healthcare Solutions, he has led the reimbursement and health economics organizations. Mr. Greenfield also leads the global marketing function and is responsible for physician education programs, new market development, and service. Before joining Abiomed, Mr. Greenfield held positions in sales, marketing and finance at GE Healthcare including consulting with large U.S. health systems, eCommerce and Six Sigma. Prior to GE Healthcare, he held positions in sales, marketing and finance at The Boeing Company, including European Country Manager and graduate of the Fiscal Development Program. He received his Bachelor degree in Finance from the University of Illinois in 1994 and a Master of Business Administration degree from St. Louis University. Mr. Greenfield is also a certified Master Blackbelt in Six Sigma and Change Acceleration Process from General Electric.
Mr. Michael G. Howley joined Abiomed in March 2009 as Vice President and General Manager, Global Sales. Prior to joining us, Mr. Howley spent 20 years at GE Healthcare. From February 2006 to February 2009, he was General Manager at GE Healthcare, overseeing the Americas X-ray and Interventional Radiology division. From April 2004 to February 2006, Mr. Howley held the General Manager position for the Clinical Information Systems at GE. From October 2002 to April 2004, he was the Americas Sales Manager of Functional and Molecular Imaging. Prior to this role, Mr. Howley held several other national and regional sales positions at GE, beginning his tenure with the company in 1989. Mr. Howley has a Bachelor of Science in Business Administration and Marketing from Auburn University.
Mr. Steve McEvoy is the Vice President and General Counsel of Abiomed (ABMD). Prior to joining Abiomed in 2007, Mr. McEvoy spent ten years at Biogen Idec, Inc., a global biotechnology company, where he served as Chief Operations Counsel and Associate General Counsel. Mr. McEvoy supported business development efforts, managed the legal aspects of global operations, and supported the research and clinical development activities. Prior to this role, Mr. McEvoy was an associate with Palmer & Dodge LLP. Mr. McEvoy received a bachelor’s degree in international relations at Brown University, a master’s in business administration from Fuqua School of Business at Duke University and a J.D. from Columbia University School of Law.
Dr. Thorsten Siess joined Abiomed in 2005 upon its acquisition of Impella CardioSystems, AG, which he co-founded in 1998 and has served as Manager of R&D, then Chief Technology Officer. His work in the development and marketing of the Impella 2.5™ and 5.0™ in Europe led to their CE Mark approval. During his time at the University of Aachen he developed the Impella® technology which served as a platform for the entire Impella product portfolio. The products, which allow early intervention through a pencil-sized VAD, are now available in 70 centers in 11 countries. Prior to founding Impella, Dr. Siess served as Scientist in the Biomedical Technology Team at Helmholtz-Institute of Biomedicine at the University of Aachen in Germany. Dr. Siess received a Ph.D. degree as well as his MASc in Mechanical Engineering from the University of Aachen.
Mr. Michael Tomsicek joins Abiomed having most recently served as Chief Financial Officer of Lexington, MA based Cubist Pharmaceuticals. He joined Cubist in 2010 and held a series of increasingly responsible roles leading finance, IR and strategic sourcing through a very dynamic period at the firm. Prior to Cubist, he spent nearly eight years at General Electric Healthcare, initially as Finance Manager of its global operations, and then as Chief Financial Officer of its diagnostic ultrasound business and Chief Financial Officer of its global ultrasound product group. Previously, Mr. Tomsicek served in a variety of financial and operational roles at Motorola. He holds a Bachelor of Science Degree in Engineering and a Master of Business Administration from the University of Wisconsin
Dr. David Weber joined Abiomed in April 2007 as the Chief Operating Officer. Prior to joining Abiomed, Dr. Weber served as General Manager, Aviation Business at GE Security—Homeland Protection from April 2005 until April 2007 where he led GE Security’s Aviation and Transportation Business and was responsible for product development, marketing and sales. From June 2004 until April 2005, he served as General Manager, MRI Marketing at GE Healthcare where he was responsible for strategic product planning, go-to-market and product launch activities including developing product roadmaps and introducing new product technologies to the market, and from March 2001 until June 2004, he served as Manager, Global High Field MRI Business, GE Medical Systems where he was responsible for new product planning and development. Dr. Weber has a B.S. in physics from Denison University, a Bachelor of Science in Nuclear Engineering from Columbia University, a Master of Science in Medical Physics from the University of Wisconsin-Madison, and a Doctor of Philosophy in Medical Physics from the University of Wisconsin-Madison.